Navigation Links
Novartis MS Drug Shows Promising Results

sease of the central nervous system affecting twice as many women than men.3 MS has a significant impact on the patient's social activities, employment and overall quality of life. Currently marketed MS therapies afford an average reduction in relapse rates of 30% in two-year studies and require frequent injections ranging from daily to weekly.

FTY720 Phase II study results

The results are from a large Phase II study conducted at 32 centers in 11 countries (Europe and Canada). In the initial, placebo-controlled part of this study, 281 patients were randomized in equal numbers to receive either placebo, 1.25 mg or 5.0 mg FTY720 orally once-daily for six months. The study evaluated the effect of FTY720 on disease activity as measured by MRI and clinical relapses as well as its tolerability and safety. After six months, patients in the placebo group were re-randomized to receive either FTY720 1.25 mg or 5 mg blinded for an additional six months, while patients already on FTY720 continued their originally-assigned treatment. A total of 98% of the 255 patients who completed the first six months volunteered to continue in the extension phase evaluating the longer-term effects of FTY720.

In the 12-month analysis, both patient groups on FTY720 (1.25 mg and 5 mg) who had experienced a reduction in their annualized relapse rate of more than 50% during the first six months compared to placebo maintained this low relapse rate during the subsequent six-month extension. In those patients who switched from placebo to either 1.25 mg or 5 mg of FTY720 after six months, the annualized relapse rate was reduced by at least 70% during the second six-month study phase compared to the first six months on placebo.

The MRI results at 12 months showed low levels of inflammatory disease activity in all FTY720 groups. In patients who switched from placebo to FTY720, the mean number of inflammatory (Gd-enhancing) lesions on MRI (at the 12th
'"/>




Page: 1 2 3

Related medicine news :

1. Novartis files application with FDA for Zometa
2. Canine Painkiller unveiled by Novartis
3. Glivec the hot cancer drug from Novartis
4. Zometa [Novartis Drug] For Treatment Of Paget’s Diseas
5. Bird-flu Vaccine Adjuvant Contract Goes to Novartis
6. Drop Patent Petition, Activists Ask Novartis
7. E.U. Panel Backs Novartis Mock-up Pandemic Flu Vaccine
8. Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board
9. Novartis Gleevec Found Effective in Treating Gastro-intestinal Tumors
10. Novartis Drug Diovan Shows Superior Benefits
11. Experimental treatment for Ebola Virus Shows promising results in mice
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Novartis Drug Shows Promising Results

(Date:8/30/2014)... Daily Gossip magazine reveals in its "Panic Away" ... under control with a simple and efficient method. , ... new method as an anxiety recovery program which promises ... anxiety related disorders. , What makes this program ... can be accessed by users from the comfort of ...
(Date:8/30/2014)... Scotch Plains, NJ (PRWEB) August 30, 2014 ... the first facilities in New Jersey and even in ... in-demand technology that takes inches off of patients’ waists ... by freezing cells in small sections, Vanquish is more ... without pain. Patients lay comfortably under panels about ...
(Date:8/30/2014)... Delhi, India (PRWEB) August 30, 2014 ... introduced low cost SEO service for small businesses. , ... or start-ups cannot afford costly search engine optimization service. ... budget of small businesses into account. , On ... said, “We have introduced this low cost SEO service ...
(Date:8/30/2014)... 30, 2014 The establishment and ... has been one of the main strategies of ... a positive impact around the world. , Architecturally ... top trained executives and trainers deliver L. Ron ... Vital statistics demonstrate that significant reduction in ...
(Date:8/30/2014)... Acne is a common problem millions of American cope with ... a daily nuisance, for some, it can have a crippling impact ... lead to dramatic mood swings and depression. , Those struggling ... their skin. In some cases, that can make the problem even ... those on a quest for clearer skin can now view ...
Breaking Medicine News(10 mins):Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:RBSEO Services Introduces Low Cost SEO Service for Small Businesses 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Acne Treatment Reviews Added to Popular Treatment Website 2
... first study of its kind, 161 postnatal women with ... groups to test the effect of a physiotherapist-led exercise ... group received an eight-week "Mother and Baby" program, including ... with parenting education. In the second group, ...
... University of Delaware have developed a new method for ... other diseases., Developed by Zhihao Zhuang, UD assistant professor ... chemical method yields hundredsfold more ubiquitylated proteins than current ... such mysteries as how cancer cells gain resistance to ...
... ... technology with the launch of their new web based clinical Label Approval System - ... ... continue to showcase innovative technology with the launch of their new web based clinical ...
... is available in <A HREF=",http://chinese.eurekalert.org/zh/emb_releases/2010-04/aaoo-amb032510.php,">Chinese . ... where very thin needles are used to stimulate ... therapeutic responses, may be an effective treatment option ... olfactory dysfunction (PVOD), according to new research in ...
... and unemployment rates that are nearly double that of ... to make less use of public assistance, especially childcare ... Policy Program. OSU researchers Deana Grobe and Bobbie ... Minnesota, found that the rates of use of such ...
... than one in four elderly Americans lacked the capacity to make ... to a study of 3,746 people to be published April 1 ... who had advance directives - including living wills or durable powers ... of the time, says lead author Maria Silveira, M.D., M.P.H., physician ...
Cached Medicine News:Health News:New mums beat the blues and increase wellbeing with physio exercise, study reveals 2Health News:UD team develops new method for producing proteins critical to medical research 2Health News:Almac to Improve Label Approval Process in Clinical Trials 2Health News:Almac to Improve Label Approval Process in Clinical Trials 3Health News:Acupuncture may be an effective treatment for post-viral infection loss of smell 2Health News:Despite much-higher poverty rates, rural Oregonians use less public assistance 2Health News:Despite much-higher poverty rates, rural Oregonians use less public assistance 3Health News:More than one-quarter of elderly patients lack decision-making capacity at death 2Health News:More than one-quarter of elderly patients lack decision-making capacity at death 3
(Date:8/29/2014)... Aug. 29, 2014 Pomerantz LLP has filed ... the "Company") (NASDAQ: EDAP ) and certain ... States District Court, Southern District of New ... behalf of a class consisting of all persons or ... and July 30, 2014, inclusive (the "Class Period"). This class ...
(Date:8/29/2014)... , Aug. 29, 2014 Thoratec Corporation (NASDAQ: ... mechanical circulatory support therapies to save, support and restore ... the 2014 Morgan Stanley Global Healthcare Conference on Wednesday, ... President and Chief Executive Officer, will provide an update ... Time (9:55 a.m., Pacific Daylight Time).   ...
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 Research ... CNS Disorders Drug Pipeline Insight 2014" report to their ... market in US is one of the largest segments of ... an alarming rate, while the available therapies were unable to ... growth in the market for CNS disorder, especially over the ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3US CNS Disorders Drug Pipeline Insight 2014 2
... Sept. 21, 2011 Boehringer Ingelheim,s investigational tyrosine kinase ... reducing lung function decline in patients with idiopathic pulmonary ... published today online in the New England Journal ... progressive and severely debilitating lung disease with a high ...
... CHAPEL HILL, N.C., Sept. 21, 2011 Pharmaceutical ... support a variety of product-related initiatives, from treatment ... playing such a pivotal role in a product,s ... use of Health Outcomes data. To ...
Cached Medicine Technology:New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis 2New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis 3New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis 4New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis 5Optimizing the Use of Health Outcomes Data in the Marketplace 2
... Pipette Tracker Pro is the only pipette calibration ... regulated environment with the tools that they need ... All of the features of Pipette Tracker ... Full audit trail implementation Support for Oracle ...
... V-shaped bottom allows easy withdrawal of ... per bag, ,• Corner pouring lips ... Basin designed for 4, 8, and 12 ... bottom permits withdrawal of practically all of ...
Reservoir, High Profile, Multi Well, 12 Row, Pyramid Bottom, 21mL Available Sterile...
Reservoir, High Profile, Single Well, 96ch-format, Pyramid Bottom, 240mL Available Sterile...
Medicine Products: